Table 36Summary of embolization treatment study and patient characteristics: nonrandomized comparative studies

Study
N
Rating
Study DesignIntervention PeriodInterventionAge, Mean or Median
(Range)
ECOG ScoreCP
A%; B%; C%
BCLC
A%; B%
Previous LDT %
Recchia et al. 201231
105
Poor
Prospective case control01/2008 – 01/2010DEB with DC beads® loaded with doxorubicin (50 mg/m2). For tumors >5 cm the size was between 500 and 700 μm, for tumors between 5 and 3 cm, the size was 300-500 μm, while for tumors <3 cm the size was 300 μm.Median: 72
(53–80)
≤1: 100A: 34;
B: 66;
C: 0
NRNR
TACEMedian: 70
(47–80)
≤1: 100A: 40;
B: 60;
C: 0
NRNR
Yu et al. 200963
60
Poor
Retrospective case control03/2002 - 12/2002TEA with lipiodol-ethanol mixture (mean: 14.5 mL, SD: 17.6 mL) via tumor feeder vessel(s) for a median of 2 treatmentsMean: 64.4
(NR)
≤1: 100;
2: 0
A: 93.3;
B: 6.7;
C: 0
NRNR
01/2005 - 12/2005TACE with lipiodol (20 mL) - cisplatin (10 mg) emulsion and gelatin sponge particle embolization via hepatic artery for a median of 3 treatmentsMean: 62.7
(NR)
≤1:96.7;
2: 3.3
A: 93.3;
B: 6.7;
C: 0
NRNR

Abbreviations: BCLC = Barcelona Clinic Liver Center hepatocellular carcinoma stage; CP = Child-Pugh liver cirrhosis class; DEB = drug-eluting bead; ECOG = Eastern Cooperative Oncology Group; LDT = liver-directed therapy; N = number of patients; NR = not reported; SD = standard deviation; TACE = transarterial chemoembolization; TEA = transarterial ethanol ablation.

From: Results

Cover of Local Therapies for Unresectable Primary Hepatocellular Carcinoma
Local Therapies for Unresectable Primary Hepatocellular Carcinoma [Internet].
Comparative Effectiveness Reviews, No. 114.
Belinson S, Yang Y, Chopra R, et al.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.